• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Xylo Technologies Ltd.

    8/22/25 7:24:40 AM ET
    $XYLO
    Medical/Dental Instruments
    Health Care
    Get the next $XYLO alert in real time by email
    S-8 POS 1 ea0254308-s8pos_xylotech.htm POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8

    As filed with the Securities and Exchange Commission on August 22, 2025

    Registration No. 333-206803

    Registration No. 333-221019

    Registration No. 333-229429

    Registration No. 333-258624

    Registration No. 333-274190

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO:

    Form S-8 Registration Statement No. 333- 206803

    Form S-8 Registration Statement No. 333- 221019

    Form S-8 Registration Statement No. 333- 229429

    Form S-8 Registration Statement No. 333- 258624

    Form S-8 Registration Statement No. 333- 274190

     

    UNDER
    THE SECURITIES ACT OF 1933

     

    Xylo Technologies Ltd.

    (Exact name of registrant as specified in its charter)

     

    State of Israel   Not Applicable
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification Number)

     

    10 HaNechoshet St.
    Tel Aviv 6971072, Israel
    +972 (3) 689-9124
    (Address of principal executive offices and zip code)

     

    Medigus Ltd. 2013 Share Option and Incentive Plan
    (Full title of the plans)

     

    Puglisi & Associates

    850 Library Avenue, Suite 204,

    Newark, DE, 19711, USA

    Tel: 303-738-6680

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Shachar Hadar

    Meitar | Law Offices
    16 Abba Hillel Road
    Ramat Gan, 5250608, Israel
    Tel: +972 (3) 610-3100
    Fax: +972 (3) 610-3111

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐   Accelerated filer ☐
    Non-accelerated filer ☒   Smaller reporting company ☒
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE
    DEREGISTRATION OF SECURITIES

     

    This filing (the “Post-Effective Amendment”) relates to the following registration statements on Form S-8 (collectively, the “Registration Statements”) filed by Xylo Technologies Ltd. (f/k/a Medigus Ltd.), a company organized under the laws of the State of Israel (the “Company”), with the Securities and Exchange Commission (the “SEC”):

     

    ●Registration Statement No. 333-206803 filed with the SEC on September 8, 2015, pertaining to the registration of 20,000,000ordinary shares, no par value per share, of the Company (each, an “Ordinary Share”) under the Medigus Ltd. 2013 Share Option and Incentive Plan (the “Plan”).

     

    ●Registration Statement No. 333-221019 filed with the SEC on October 19, 2017, pertaining to the registration of an additional 12,000,000 Ordinary Shares under the Plan.

     

    ●Registration Statement No. 333-229429 filed with the SEC on January 30, 2019, pertaining to the registration of an additional 5,330,000 Ordinary Shares under the Plan.

     

    ●Registration Statement No. 333-258624 filed with the SEC on August 9, 2021, pertaining to the registration of an additional 43,000,000 Ordinary Shares under the Plan.

     

    ●Registration Statement No. 333-274190 filed with the SEC on August 24, 2023, pertaining to the registration of an additional 6,000,000 Ordinary Shares under the Plan.

     

    On June 22, 2025, the District Court of Tel Aviv (Economic Division) approved an arrangement (the “Arrangement”) pursuant to Section 350 of the Israeli Companies Law, 5759-1999, between the Company and its shareholders. The Arrangement, which was previously approved by the Company’s shareholders, provides for the acquisition by L.I.A. Pure Capital Ltd. (the “Applicant”) of all issued and outstanding share capital of the Company not already owned by the Applicant. Pursuant to the Arrangement, on or about the date hereof, the Applicant completed or will complete the purchase of all of the issued and outstanding share capital of the Company, with the Company becoming a wholly owned subsidiary of the Applicant.

     

    As a result of the consummation of the Arrangement, the Company has terminated all offerings of its Ordinary Shares pursuant to each of the Registration Statements under the Securities Act of 1933, as amended. In accordance with an undertaking made by the Company in each of the Registration Statements to remove from registration, by means of a post-effective amendment, any Ordinary Shares which remain unsold at the termination of the offering, the Company hereby removes from registration all Ordinary Shares registered under the Registration Statements that remain unsold as of the date hereof, if any, and terminates the effectiveness of each of the Registration Statements. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of all such securities.

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in Tel Aviv, Israel, on this 22nd day of August, 2025.

     

      XYLO TECHNOLOGIES LTD.
         
      By: /s/ Tali Dinar
        Tali Dinar
        Chief Financial Officer

     

    No other person is required to sign this Post-Effective Amendment to the Registration Statements in reliance on Rule 478 of the Securities Act of 1933, as amended.

     

    2

     

    Get the next $XYLO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XYLO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $XYLO
    SEC Filings

    View All

    SEC Form 15-12G filed by Xylo Technologies Ltd.

    15-12G - XYLO TECHNOLOGIES LTD (0001618500) (Filer)

    8/22/25 4:00:04 PM ET
    $XYLO
    Medical/Dental Instruments
    Health Care

    SEC Form 25-NSE filed by Xylo Technologies Ltd.

    25-NSE - XYLO TECHNOLOGIES LTD (0001618500) (Subject)

    8/22/25 9:06:32 AM ET
    $XYLO
    Medical/Dental Instruments
    Health Care

    SEC Form POS AM filed by Xylo Technologies Ltd.

    POS AM - XYLO TECHNOLOGIES LTD (0001618500) (Filer)

    8/22/25 7:28:03 AM ET
    $XYLO
    Medical/Dental Instruments
    Health Care

    $XYLO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Xylo Technologies: Viewbix Shares to Begin Trading on Nasdaq

    TEL AVIV, Israel, June 05, 2025 (GLOBE NEWSWIRE) -- Xylo Technologies Ltd. (NASDAQ:XYLO) ("Xylo" or the "Company"), a technology-based company engaged in advanced innovative technologies, announced today that Viewbix Inc. (NASDAQ:VBIX), a global developer of ad-tech innovative technologies, has received approval for its shares of common stock to be listed on the Nasdaq Capital Market. Viewbix, in which Xylo holds an indirect stake through its 45.74% ownership in Gix Internet Ltd. ("Gix Internet"), which in turn owns 2,818,585 common shares representing 42.58% of Viewbix, expects its shares to commence trading on Nasdaq under the symbol "VBIX" on or about June 5, 2025, subject to continued

    6/5/25 9:21:00 AM ET
    $MDGS
    $XYLO
    Medical/Dental Instruments
    Health Care

    Xylo Technologies: Charging Robotics Successfully Installs Wireless EV Charging System in Automatic Parking Facility

    TEL AVIV, Israel, April 30, 2025 (GLOBE NEWSWIRE) -- Xylo Technologies Ltd. (NASDAQ:XYLO) ("Xylo" or the "Company"), a technology-based company engaged in advanced innovative technologies, announced today that Charging Robotics, Inc. (OTC:CHEV) ("Charging Robotics"), a Delaware corporation (62.22% owned by Xylo), has successfully installed a system for wireless charging of electric vehicles with a leading supplier of robotic parking facilities.  Following the installation, the system successfully demonstrated the ability to wirelessly transfer power.  The system is intended to be used for charging electric vehicles ("EVs") while reporting charge data to the cloud and managing the charging

    4/30/25 9:12:00 AM ET
    $MDGS
    $XYLO
    Medical/Dental Instruments
    Health Care

    Xylo Technologies: Revoltz Secures First Institutional Client for PORTO EV Logistics Deployment

    TEL AVIV, Israel, April 29, 2025 (GLOBE NEWSWIRE) -- Xylo Technologies Ltd. (NASDAQ:XYLO) ("Xylo" or the "Company"), a technology-based company engaged in advanced innovative technologies, announced today that Revoltz Ltd. ("Revoltz"), which is 19.9% held by Charging Robotics, Inc. (OTC:CHEV) ("Charging Robotics"), a Delaware corporation quoted on the OTC Market (62.22% owned by Xylo), has secured its first institutional client for the PORTO EV, Revoltz's flagship electric micro-vehicle designed for last-mile logistics. The new order marks a significant step in Revoltz's commercial expansion strategy, transitioning from individual sales into larger fleet deployments. The institutional cus

    4/29/25 6:34:08 AM ET
    $MDGS
    $XYLO
    Medical/Dental Instruments
    Health Care